Entrada Therapeutics TRDA Income Statement (2020-2026)

NASDAQ TRDA
$5.44 +0.19 (+3.62%)
At close: Nov 11, 2026 · 4:00 PM EST
Reported Financials

Entrada Therapeutics Quarterly Income Statement

Periods 25 quarters
Latest Sep 2026

Entrada Therapeutics reported revenue of $0.91M and net income of -$39.86M for the quarter ended Sep 2026, down 43.9% year over year. This income statement covers 25 quarters of results from Sep 2020 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Income StatementIncome Statement Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Revenue & cost
Revenue
25.26M18.17M43.74M41.85M59.12M94.69M19.57M37.40M20.56M1.95M1.61M1.30M0.88M0.90M0.91M
Operating items
Research & DevelopmentR&D
12.36M15.72M16.25M18.96M15.69M23.10M26.30M22.19M28.29M28.61M32.04M31.26M33.41M32.07M37.88M38.36M33.96M33.05M35.37M32.37M
Selling, General & AdministrativeSG&A
6.10M6.43M7.33M6.98M9.89M7.94M8.17M7.53M8.65M9.40M9.24M9.97M9.86M10.27M10.92M10.30M9.55M10.12M10.49M10.23M
Operating ExpensesOpex
18.46M22.15M23.58M25.94M25.58M31.04M34.47M29.72M36.94M38.01M41.27M41.23M43.27M42.35M48.80M48.67M43.51M43.18M45.86M42.59M
Operating IncomeOp. Inc
-18.46M-22.15M-23.58M-25.94M-25.58M-5.78M-16.30M14.01M4.91M21.11M53.42M-21.66M-5.87M-21.79M-46.85M-47.05M-42.21M-42.30M-44.96M-41.69M
Non-operating items
Gains (Losses) on Sale of Assets & InvestmentsGains on Sales
-1.54M-0.73M-0.48M0.69M1.42M-0.36M0.51M0.69M-0.44M-0.08M1.30M-1.02M0.48M-0.04M0.22M0.03M-0.41M-0.18M-0.12M
Interest & Investment IncomeInt & Inv Inc
0.01M0.48M0.40M0.80M0.95M2.66M4.22M4.05M4.29M4.21M4.37M5.77M5.13M4.44M3.92M3.57M3.14M2.62M2.24M1.97M
Other Non Operating IncomeOther Non Op Inc.
0.01M0.48M0.40M0.80M0.95M2.66M4.22M4.05M4.29M4.21M4.37M5.77M5.13M4.44M3.92M3.57M3.14M2.62M2.24M1.97M
Non Operating IncomeNon Op. Inc.
0.01M0.48M0.40M0.80M0.95M2.66M4.22M4.05M4.29M4.21M4.37M5.77M5.13M4.44M3.92M3.57M3.14M2.62M2.24M1.97M
Net income details
EBIT
-18.46M-22.15M-23.58M-25.94M-25.58M-5.78M-16.30M14.01M4.91M21.11M53.42M-21.66M-5.87M-21.79M-46.85M-47.05M-42.21M-42.30M-44.96M-41.69M
EBT
-18.45M-21.67M-23.18M-25.14M-24.63M-3.12M-12.08M18.06M9.24M25.33M57.79M-15.89M-0.72M-17.35M-42.93M-43.48M-39.07M-39.68M-42.73M-39.72M
Tax ProvisionsTaxes
3.60M13.85M-17.40M18.74M1.83M2.80M-1.90M-1.83M0.18M0.70M0.09M0.04M0.04M0.03M
Income After Tax
-18.45M-21.67M-23.18M-25.14M-24.63M-6.72M-25.93M35.46M-9.50M23.50M54.99M-13.99M1.11M-17.35M-43.10M-44.18M-39.16M-39.72M-42.76M-39.75M
Income from Continuing OperationsIncome (Continuing)
-18.45M-21.67M-23.18M-25.14M-24.63M-6.72M-25.93M35.46M-9.50M23.50M54.99M-13.99M1.11M-17.35M-43.10M-44.18M-39.16M-39.72M-42.76M-39.75M
Consolidated Net IncomeConsol Net Inc.
-18.45M-23.21M-23.91M-25.62M-23.94M-5.26M-26.29M35.97M-8.85M23.06M54.95M-12.73M0.12M-16.87M-43.14M-43.91M-39.13M-40.12M-42.94M-39.86M
Net Income Attributable to Noncontrolling InterestsNCI Net Income
1.30M0.22M
Income towards Parent CompanyParent Net Inc
-18.49M-21.67M-23.18M-25.14M-24.63M-6.67M-25.93M35.46M-9.54M23.50M55.03M-14.03M1.13M-17.35M-43.10M-44.13M-39.16M-39.72M-42.76M-39.74M
Net Income towards Common StockholdersNet Income
-18.49M-21.67M-23.18M-25.14M-24.63M-6.67M-25.93M35.46M-9.54M23.50M55.03M-14.03M1.13M-17.35M-43.10M-44.13M-39.16M-39.72M-42.76M-39.74M
Additional items
EPS (Basic)
-2.95-0.69-0.74-0.80-0.79-0.21-0.781.07-0.290.701.61-0.350.03-0.42-1.04-1.06-0.95-0.95-1.01-0.94
EPS (Diluted)
-2.95-0.69-0.74-0.80-0.79-0.21-0.781.02-0.290.681.55-0.350.03-0.42-1.04-1.06-0.95-0.95-1.01-0.94
Shares Outstanding
6.27M31.25M31.28M31.30M31.29M32.37M33.16M33.28M33.05M33.50M34.18M40.63M37.31M41.07M41.34M41.46M41.37M41.84M42.22M42.37M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
6.27M31.25M31.28M31.30M31.29M32.37M33.16M34.78M33.05M34.79M35.51M40.63M39.00M41.07M41.34M41.46M41.37M41.84M42.22M42.37M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
6.27M31.26M31.28M31.33M31.39M33.13M33.21M33.34M33.44M33.60M37.17M37.40M37.57M37.94M38.03M38.22M38.28M38.82M38.94M39.15M
EBITDA
-18.14M-21.61M-22.94M-25.47M-25.18M-5.48M-15.60M14.81M5.64M22.05M54.32M-20.76M-4.87M-20.84M-45.75M-45.85M-41.32M-41.50M-44.16M-40.99M
Tax Rate
202.80%7.23%4.85%

Entrada Therapeutics Income Statement API

Pull Entrada Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=TRDA&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY